Search research articles
Contact Us
Filters
Showing results (31-40 of 64) with videos related to
Page
of 7
Sort By:
Leukemia
|
June 8, 2019
Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas
Xuan Zhang, Chengfeng Bi, Ting Lu, et al.
Blood
|
September 28, 2019
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew Lunning, Julie Vose, Loretta Nastoupil, et al.
Hematological Oncology
|
June 4, 2016
Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study
Monica Bellei, Elena Sabattini, Emanuela Anna Pesce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2024
Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma
Chengcheng Yan, Melissa A Richard, Christopher J Gibson, et al.
Blood
|
April 29, 2018
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
Ann S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
British Journal of Haematology
|
February 13, 2020
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
Ann S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
British Journal of Haematology
|
February 18, 2009
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial
Owen A O'Connor, Craig Moskowitz, Carol Portlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2010
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes
Owen A O'Connor, Carol Portlock, Craig Moskowitz, et al.
Blood Advances
|
June 1, 2023
An international real-world analysis of relapsed/refractory lymphoma occurring during pregnancy
Faheem Farooq, Justin S Brandt, Elyce Cardonick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2024
Sex-Based Differences in Risk of Therapy-Related Myeloid Neoplasms
Melissa A Richard, Chengcheng Yan, Yanjun Chen, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 64) with videos related to
Sort By:
Page
of 7
Leukemia
|
June 8, 2019
Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas
Xuan Zhang, Chengfeng Bi, Ting Lu, et al.
Blood
|
September 28, 2019
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew Lunning, Julie Vose, Loretta Nastoupil, et al.
Hematological Oncology
|
June 4, 2016
Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study
Monica Bellei, Elena Sabattini, Emanuela Anna Pesce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2024
Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma
Chengcheng Yan, Melissa A Richard, Christopher J Gibson, et al.
Blood
|
April 29, 2018
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
Ann S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
British Journal of Haematology
|
February 13, 2020
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
Ann S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
British Journal of Haematology
|
February 18, 2009
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial
Owen A O'Connor, Craig Moskowitz, Carol Portlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2010
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes
Owen A O'Connor, Carol Portlock, Craig Moskowitz, et al.
Blood Advances
|
June 1, 2023
An international real-world analysis of relapsed/refractory lymphoma occurring during pregnancy
Faheem Farooq, Justin S Brandt, Elyce Cardonick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2024
Sex-Based Differences in Risk of Therapy-Related Myeloid Neoplasms
Melissa A Richard, Chengcheng Yan, Yanjun Chen, et al.
Page
of 7